Subhajit Giri

Dr. Subhajit Giri

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 August 2010 in Biodegradation
Verified
Journal Article
Closed access
PDF file
KMKoushik Mukherjee
Koushik Mukherjee
PTProsun Tribedi
Prosun Tribedi
ACArup Chowdhury
Arup Chowdhury
TRTanusree Ray
Tanusree Ray
AJArchi Joardar
Archi Joardar
ASAlok Kumar Sil
Alok Kumar Sil

1 September 2024 in Cancer Management and Research
Verified
Journal Article
Open access
PDF file
BTBicky Thapa
Bicky Thapa
NSNavonil De Sarkar
Navonil De Sarkar
Subhajit GiriSubhajit Giri
Subhajit Giri
KSKomal Sharma
Komal Sharma
MKMingee Kim
Mingee Kim
DKDeepak Kilari
Deepak Kilari
Metastatic castrate-resistant prostate cancer (mCRPC) is associated with poor prognosis. DNA damage response (DDR) genes are commonly altered in mCRPC rendering them as promising therapeutic targets. Poly (ADP ribose) polymerase inhibitors (PARPi) demonstrated antitumor activity in mCRPC patients with DDR gene mutations through synthetic lethality. Multiple clinical trials with PARPi monotherapy exhibited encouraging clinical outcomes in selected patients with mCRPC. More recently, three Phase III randomized clinical trials (RCTs) combining PARPi with androgen receptor signaling inhibitors (ARSIs) demonstrated improved antitumor activity compared to ARSI monotherapy in mCRPC patients as the first-line therapy. Clinical benefit was more pronounced in patients harboring DDR alterations, specifically BRCA1/2. Interestingly, antitumor activity was also observed irrespective of DDR gene mutations, highlighting BRCAness phenotype with androgen receptor blockade resulting in synergistic activity between ARSIs and PARPi. In this review, we discuss the clinical efficacy and safety data of the combination of PARPi plus ARSI in all Phase 3 randomized controlled trials (RCTs), emphasizing strategies for patient selection and highlighting emerging trends based on clinical trial data.

1 July 2019 in Neuroscience Letters
Verified
Journal Article
Closed access
AGArunibha Ghosh
Arunibha Ghosh
TSTamal Sadhukhan
Tamal Sadhukhan
Subhajit GiriSubhajit Giri
Subhajit Giri
ABArindam Biswas
Arindam Biswas
SDShyamal Kumar Das
Shyamal Kumar Das
JRJharna Ray
Jharna Ray

1 January 2017 in Neuroscience Letters
Verified
Journal Article
Closed access
Subhajit GiriSubhajit Giri
Subhajit Giri
TNTufan Naiya
Tufan Naiya
ZEZAFFAR EQUBAL
ZAFFAR EQUBAL
CSCharulata Savant Sankhla
Charulata Savant Sankhla
SDShyamal Kumar Das
Shyamal Kumar Das
JRJharna Ray
Jharna Ray

25 March 2019 in Journal of Molecular Neuroscience
Verified
Journal Article
Closed access
PDF file
Subhajit GiriSubhajit Giri
Subhajit Giri
TNTufan Naiya
Tufan Naiya
SRShubhrajit Roy
Shubhrajit Roy
GDGautami Das
Gautami Das
GWGurusidheshwar M. Wali
Gurusidheshwar M. Wali
JRJharna Ray
Jharna Ray

7 February 2023 in Cells
Verified
Journal Article
Open access
PDF file
ICIlyas Chohra
Ilyas Chohra
KCKeshi Chung
Keshi Chung
Subhajit GiriSubhajit Giri
Subhajit Giri
brigitte malgrangebrigitte malgrange
brigitte malgrange
During transcription, DNA replication and repair, chromatin structure is constantly modified to reveal specific genetic regions and allow access to DNA-interacting enzymes. ATP-dependent chromatin remodelling complexes use the energy of ATP hydrolysis to modify chromatin architecture by repositioning and rearranging nucleosomes. These complexes are defined by a conserved SNF2-like, catalytic ATPase subunit and are divided into four families: CHD, SWI/SNF, ISWI and INO80. ATP-dependent chromatin remodellers are crucial in regulating development and stem cell biology in numerous organs, including the inner ear. In addition, mutations in genes coding for proteins that are part of chromatin remodellers have been implicated in numerous cases of neurosensory deafness. In this review, we describe the composition, structure and functional activity of these complexes and discuss how they contribute to hearing and neurosensory deafness.